Shortened survival after relapse in T-cell acute lymphoblastic leukemia patients with p16/p15 deletions

Mitchell B. Diccianni, Ayse Batova, John Yu, Thai Vu, Jeanette Pullen, Michael Amylon, Bradley H Pollock, Alice L. Yu

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

p16 Alterations were detected in > 60% of 103 primary T-ALL samples. In paired diagnosis-relapse patient samples, 80% of the relapse samples with p16 deletion were deleted at diagnosis. When p16 was homozygously deleted, p15 gene alterations were found in 72% of the diagnosis T-ALL patient samples, increasing significantly to 100% at relapse. Alterations of p18 were not detected. No clinical significance of p15/p16 gene deletion in diagnosis T-ALL was found with respect to white blood cell (WBC) count, incidence of mediastinal mass, rate of relapse, duration of first remission or event-free survival. In relapse T-ALL, however, patients with p16 deletion experienced a significantly shorter duration of post-relapse survival, demonstrating that p16 deletion is clinically significant in T-ALL.

Original languageEnglish (US)
Pages (from-to)549-558
Number of pages10
JournalLeukemia Research
Volume21
Issue number6
DOIs
StatePublished - Jun 1997
Externally publishedYes

Fingerprint

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Recurrence
Survival
p16 Genes
Gene Deletion
Leukocyte Count
Disease-Free Survival
Incidence
Genes

Keywords

  • p15
  • p16
  • p18
  • Prognosis
  • Relapse
  • T-ALL

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Diccianni, M. B., Batova, A., Yu, J., Vu, T., Pullen, J., Amylon, M., ... Yu, A. L. (1997). Shortened survival after relapse in T-cell acute lymphoblastic leukemia patients with p16/p15 deletions. Leukemia Research, 21(6), 549-558. https://doi.org/10.1016/S0145-2126(97)00007-6

Shortened survival after relapse in T-cell acute lymphoblastic leukemia patients with p16/p15 deletions. / Diccianni, Mitchell B.; Batova, Ayse; Yu, John; Vu, Thai; Pullen, Jeanette; Amylon, Michael; Pollock, Bradley H; Yu, Alice L.

In: Leukemia Research, Vol. 21, No. 6, 06.1997, p. 549-558.

Research output: Contribution to journalArticle

Diccianni, Mitchell B. ; Batova, Ayse ; Yu, John ; Vu, Thai ; Pullen, Jeanette ; Amylon, Michael ; Pollock, Bradley H ; Yu, Alice L. / Shortened survival after relapse in T-cell acute lymphoblastic leukemia patients with p16/p15 deletions. In: Leukemia Research. 1997 ; Vol. 21, No. 6. pp. 549-558.
@article{0bd31dd9d77b4f9a808f899dc3e76bd0,
title = "Shortened survival after relapse in T-cell acute lymphoblastic leukemia patients with p16/p15 deletions",
abstract = "p16 Alterations were detected in > 60{\%} of 103 primary T-ALL samples. In paired diagnosis-relapse patient samples, 80{\%} of the relapse samples with p16 deletion were deleted at diagnosis. When p16 was homozygously deleted, p15 gene alterations were found in 72{\%} of the diagnosis T-ALL patient samples, increasing significantly to 100{\%} at relapse. Alterations of p18 were not detected. No clinical significance of p15/p16 gene deletion in diagnosis T-ALL was found with respect to white blood cell (WBC) count, incidence of mediastinal mass, rate of relapse, duration of first remission or event-free survival. In relapse T-ALL, however, patients with p16 deletion experienced a significantly shorter duration of post-relapse survival, demonstrating that p16 deletion is clinically significant in T-ALL.",
keywords = "p15, p16, p18, Prognosis, Relapse, T-ALL",
author = "Diccianni, {Mitchell B.} and Ayse Batova and John Yu and Thai Vu and Jeanette Pullen and Michael Amylon and Pollock, {Bradley H} and Yu, {Alice L.}",
year = "1997",
month = "6",
doi = "10.1016/S0145-2126(97)00007-6",
language = "English (US)",
volume = "21",
pages = "549--558",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "6",

}

TY - JOUR

T1 - Shortened survival after relapse in T-cell acute lymphoblastic leukemia patients with p16/p15 deletions

AU - Diccianni, Mitchell B.

AU - Batova, Ayse

AU - Yu, John

AU - Vu, Thai

AU - Pullen, Jeanette

AU - Amylon, Michael

AU - Pollock, Bradley H

AU - Yu, Alice L.

PY - 1997/6

Y1 - 1997/6

N2 - p16 Alterations were detected in > 60% of 103 primary T-ALL samples. In paired diagnosis-relapse patient samples, 80% of the relapse samples with p16 deletion were deleted at diagnosis. When p16 was homozygously deleted, p15 gene alterations were found in 72% of the diagnosis T-ALL patient samples, increasing significantly to 100% at relapse. Alterations of p18 were not detected. No clinical significance of p15/p16 gene deletion in diagnosis T-ALL was found with respect to white blood cell (WBC) count, incidence of mediastinal mass, rate of relapse, duration of first remission or event-free survival. In relapse T-ALL, however, patients with p16 deletion experienced a significantly shorter duration of post-relapse survival, demonstrating that p16 deletion is clinically significant in T-ALL.

AB - p16 Alterations were detected in > 60% of 103 primary T-ALL samples. In paired diagnosis-relapse patient samples, 80% of the relapse samples with p16 deletion were deleted at diagnosis. When p16 was homozygously deleted, p15 gene alterations were found in 72% of the diagnosis T-ALL patient samples, increasing significantly to 100% at relapse. Alterations of p18 were not detected. No clinical significance of p15/p16 gene deletion in diagnosis T-ALL was found with respect to white blood cell (WBC) count, incidence of mediastinal mass, rate of relapse, duration of first remission or event-free survival. In relapse T-ALL, however, patients with p16 deletion experienced a significantly shorter duration of post-relapse survival, demonstrating that p16 deletion is clinically significant in T-ALL.

KW - p15

KW - p16

KW - p18

KW - Prognosis

KW - Relapse

KW - T-ALL

UR - http://www.scopus.com/inward/record.url?scp=0030929927&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030929927&partnerID=8YFLogxK

U2 - 10.1016/S0145-2126(97)00007-6

DO - 10.1016/S0145-2126(97)00007-6

M3 - Article

C2 - 9279366

AN - SCOPUS:0030929927

VL - 21

SP - 549

EP - 558

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 6

ER -